At CAN-AM, we have established a network of experienced CRAs to meet the varied monitoring needs of our clients. Each of our team members has over 10 years’ experience monitoring clinical trials, at all phases covering a wide range of therapeutic areas. It is this team of experienced, committed and dedicated CRA's who will see the projects through to completion, focusing on the needs of our clients and delivering with the highest of standards. Whether you require 1 or 20 CRA’s we are a collaborative network that can meet your needs and deliver exceptional quality in our work.
Our Clinical Monitoring capabilities include but not limited to:
Identification and selection of investigators/sites
Identification and management of central institutional review boards
Regulatory document review and collection
Site contract and budget negotiation
On-site training
Site qualification, initiation, and closeout
Interim site monitoring
Drug accountability
Data query resolution
Anxiety Disorder
Cardiovascular
Central Nervous System
Dermatology
Devices
Endocrinology
Gastroenterology
Hematology
Immunology
Infectious Disease
Neonatology
Nephrology
Neurology/Urology
Oncology
Ophthalmology
Orthopedics
Pulmonary/Respiratory
Psychiatry
Rheumatology
Please contact us to learn more about how we can serve your clinical development needs.
Our team of project managers will guide your project through the preparation of protocols, case report forms, and other study documentation, ethics committee approval, development of recruitment strategies to increase patient enrolment into the trial, the provision of clinical trial materials, and the overall management of the trial. Our team ensures that there is full compliance with all aspects of GCP - from project award to project completion.
Per the ICH guidelines, our auditors will conduct a “systematic and independent examination of project related activities and documents to determine whether the evaluated trial related activities were conducted and the data were recorded, analyzed and accurately reported according to the protocol sponsor, SOPs, GCP and applicable regulatory requirements”.